Serono studies anastrozole
Executive Summary
Serono plans to begin Phase II study of aromatase inhibitor anastrozole in ovulation induction and improvement of follicular development this year after acquiring rights to the product for fertility indications from AstraZeneca. AZ markets anastrozole (Arimidex) for breast cancer...